OMEROS CORP Earnings Per Share (Diluted)
OMEROS CORP (OMER) reported Earnings Per Share (Diluted) of $0.15 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-12
- OMEROS CORP earnings per share, diluted for the quarter ending 2026-06-30 was $0.15.
- OMEROS CORP earnings per share, diluted for the quarter ending 2026-03-31 was $0.62.
- OMEROS CORP earnings per share, diluted for the quarter ending 2025-09-30 was -$0.47.
- OMEROS CORP earnings per share, diluted for the quarter ending 2025-06-30 was -$0.43.
- OMEROS CORP earnings per share, diluted for fiscal 2025 was -$0.05.
- OMEROS CORP earnings per share, diluted for fiscal 2024 was -$2.70.
- OMEROS CORP earnings per share, diluted for fiscal 2023 was -$1.88, a 347.37% decline from fiscal 2022.
- OMEROS CORP earnings per share, diluted for fiscal 2022 was $0.76, a 75.64% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.15 10-Q · filed 2026-08-12 | $0.77 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $0.62 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$0.05 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$0.47 10-Q · filed 2025-11-13 | -$1.47 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | -$0.43 10-Q · filed 2026-08-12 | -$1.01 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | -$0.58 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$2.70 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$0.56 10-Q · filed 2025-11-13 | -$2.15 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | -$0.97 10-Q · filed 2025-08-14 | -$1.60 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$0.63 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$1.88 10-K · filed 2026-03-31 | |||
| 2023-06-30 | -$0.59 10-Q · filed 2023-08-09 | -$1.13 10-Q · filed 2023-08-09 | $0.92 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.64 derived: net income ÷ weighted average shares · filed 2025-03-31 |
| 2023-03-31 | -$0.54 10-Q · filed 2023-05-09 | $1.51 derived: net income ÷ weighted average shares · filed 2025-03-31 | $1.24 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.74 derived: net income ÷ weighted average shares · filed 2025-03-31 |
| 2022-12-31 | $2.05 derived: net income ÷ weighted average shares · filed 2025-03-31 | $1.77 derived: net income ÷ weighted average shares · filed 2025-03-31 | $1.28 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.76 10-K · filed 2023-03-13 |
| 2022-09-30 | -$0.28 10-Q · filed 2022-11-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.30 10-Q · filed 2022-11-09 | $3.18 derived: net income ÷ weighted average shares · filed 2024-04-01 |
| 2022-06-30 | -$0.49 10-Q · filed 2023-08-09 | -$1.02 10-Q · filed 2023-08-09 | $3.46 derived: net income ÷ weighted average shares · filed 2024-04-01 | $3.10 derived: net income ÷ weighted average shares · filed 2024-04-01 |
| 2022-03-31 | -$0.53 10-Q · filed 2023-05-09 | $3.95 derived: net income ÷ weighted average shares · filed 2024-04-01 | $3.59 derived: net income ÷ weighted average shares · filed 2024-04-01 | $3.14 derived: net income ÷ weighted average shares · filed 2024-04-01 |
| 2021-12-31 | $4.48 derived: net income ÷ weighted average shares · filed 2024-04-01 | $4.12 derived: net income ÷ weighted average shares · filed 2024-04-01 | $3.67 derived: net income ÷ weighted average shares · filed 2024-04-01 | $3.12 10-K · filed 2023-03-13 |
| 2021-09-30 | -$0.36 10-Q · filed 2022-11-09 | -$0.82 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$1.39 10-Q · filed 2022-11-09 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-03-13 |
| 2021-06-30 | -$0.46 10-Q · filed 2022-08-09 | -$1.02 10-Q · filed 2022-08-09 | -$1.63 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$2.28 derived: net income ÷ weighted average shares · filed 2023-03-13 |
| 2021-03-31 | -$0.57 10-Q · filed 2022-05-10 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$1.83 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$2.44 derived: net income ÷ weighted average shares · filed 2023-03-13 |
| 2020-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$1.26 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$1.88 derived: net income ÷ weighted average shares · filed 2023-03-13 | -$2.41 10-K · filed 2023-03-13 |
| 2020-09-30 | -$0.66 10-Q · filed 2021-11-09 | -$1.27 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$1.81 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$0.61 10-Q · filed 2021-08-09 | -$1.14 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | -$1.71 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |